1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
HLB PHARMACEUTICAL CO., LTD.

HLB PHARMACEUTICAL CO., LTD.

KKRX:047920
10,300.00
KRW
+150.00
(+1.48%)
79.90EPS
145.94P/E
416.54BMarket Cap
HLB PHARMACEUTICAL CO., LTD.
KRX:047920
(Korea Stock Exchange)

Recent

price

10,300.00

P/E

ratio

145.94

div

yld

- -

ROIC.AI

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
KRW
1,869.58
1,840.77
1,656.07
1,197.58
1,396.94
2,402.23
2,371.42
2,510.46
3,624.89
4,294.9
4,002.81
5,842.91
7,328.21
Revenue per Share
33.17
-245.76
47
-419.29
-480.11
31.45
-4,374.48
-528.26
-397.18
-613.74
58.98
129.93
80.2
Basic EPS, GAAP
-80.03
-322.08
-405.23
-247.33
-214.41
-38.86
-197.76
-2,030.34
-191.01
-713.1
109.49
-188.76
-124.83
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
409.44
1,035.66
1,470.97
1,239.38
1,131.19
1,191.38
1,958.97
2,767.82
2,841.18
2,679.96
3,371.65
3,516.22
3,673.81
Book Value per Share
344.47
989.9
1,421.5
1,225.48
1,103.79
1,119.78
1,889.98
2,692.9
2,772.76
2,522.92
3,231.59
3,404.95
3,530.13
Tangible Book Value per Share
9
10
12
13
15
15
17
25
30
32
34
35
34
Basic Weighted Avg Shares
17,164
17,713
20,346
15,558
20,541
36,100
40,571
62,853
107,482
135,953
137,082
205,582
251,946
Sales/Revenue/Turnover
2.53
-5.17
2.83
-24.49
-28.36
3.99
2.58
0.77
-5.99
-14.37
1.08
0.52
0.74
Operating Margin (%)
714
813
797
1,055
1,143
1,640
2,066
3,792
4,535
5,046
5,089
4,112
4,544
Depreciation Expense
305
-2,365
577
-5,447
-7,060
473
-74,840
-13,226
-11,777
-19,427
2,020
4,572
2,757
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
8.3
7.69
Effective Tax Rate (%)
1.77
-13.35
2.84
-35.01
-34.37
1.31
-184.47
-21.04
-10.96
-14.29
1.47
2.22
1.09
Profit Margin (%)
1,658
8,097
17,503
5,526
5,052
5,927
32,995
5,960
7,089
22,678
24,749
37,073
36,591
Working Capital
2,687
3,366
13,167
2,840
1,260
3,534
3,855
2,139
1,656
989
291
4,144
3,520
LT Debt
4,814
12,177
18,899
16,802
16,998
17,903
44,622
78,385
85,929
88,153
116,402
125,149
130,758
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.7
1.19
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
3.77
2.37
Return on Capital (%)
- -
-27.84
3.72
-30.52
-41.77
2.71
-239.39
-21.5
-14.33
-22.32
1.97
3.79
2.17
Return on Common Equity (%)

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
16,540
16,498
16,470
LT Borrowings
- -
- -
- -
LT Finance Leases
4,144
3,824
3,520
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
36
36
36
Market Capitalization
526,092
521,828
416,544

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
76,702
77,235
77,973
Cash, Cash Equivalents & STI
22,137
19,871
19,184
Accounts Receivable, Net
22,833
24,786
24,453
Inventories
29,526
29,437
30,947
Total Current Liabilities
39,628
40,738
41,381
Payables & Accruals
- -
- -
- -
ST Debt
16,540
16,498
16,470
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
32.73%
25.48%
7.51%
Free Cash Flow
163.96%
243.68%
-277.12%
Net Income, GAAP
-1,719.13%
-2.48%
126.35%
Sales/Revenue/Turnover
31.47%
40.64%
49.97%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
33,452
35,773
34,767
33,090
137,082
2025
34,646
46,919
60,593
63,423
205,582
2026
65,652
62,278
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-47
14.74
27.65
63.27
58.98
2025
45.15
25.8
-4.51
63.34
129.93
2026
20.23
-1.84
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
HLB Pharmaceutical Co., Ltd. researches, develops, manufactures, and markets specialty and generic pharmaceuticals in South Korea. The company offers an extensive portfolio of prescription drugs including skeletal muscle relaxants, tranquilizers, antihistamines, antihypertensive agents, pain relief medications, antipruritics, astringents, anti-inflammatories, alimentary system drugs, metabolic drugs, ophthalmic agents, local anesthetics, antiarteriosclerotic agents, expectorants, antipyretics, analgesics, antidiabetic drugs, chemotherapeutics, peptic ulcer agents, central nervous system drugs, antibiotics, digestives, antacids, dental drugs, multivitamins, parasitic skin disease drugs, dermatologicals, urogenital agents, amino acid agents, antitussives, mucolytics, anthelmintics, antidiarrheals, circulatory system drugs, vitamins, skin softeners, anti-hemorrhoid drugs, and liver disease agents; it also provides over-the-counter products, health functional foods under the Quanchell brand launched in 2023, peptide drugs, and contract manufacturing organization (CMO) services. HLB Pharmaceutical operates primarily in the domestic South Korean market with facilities including its headquarters and manufacturing plant in Namyangju-si, Gyeonggi Province, an R&D center in Gunpo, and additional laboratories in Dongtan and Chuncheon. Founded in 1998, the company, formerly known as Mediforum Pharmaceutical Incorporation and renamed in October 2020, achieved record sales of 100 billion won in 2022, acquired the Hyangnam Plant in February 2021 and C-TRI in November 2019, relocated its R&D center to Gunpo in February 2023, established a Korean Arthritis R&D Center in May 2023, and in April 2025 acquired Shin Hwa Advance, a pharmaceuticals distribution firm, to pursue vertical integration.